Subacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system with a measles virus mutant (SSPE virus). In Japan, interferon-α and ribavirin are administered intracerebroventricularly to patients with SSPE. However, as the therapeutic effect is insufficient, more effective drugs are needed. Favipiravir, which is clinically used as an anti-influenza drug, demonstrates anti-viral effects against RNA viruses. In this study, the antiviral effect of favipiravir against measles virus (Edmonston strain) and SSPE virus (Yamagata-1 strain) was examined in vitro. The 50% effective concentration (EC50) of favipiravir (inhibiting viral plaque formation by 50%) against Edmonston and Yamagata-1 strains were 108.7 ± 2.0 μM (17.1 ± 0.3 μg/mL) and 38.6 ± 6.0 μM (6.1 ± 0.9 μg/mL), respectively, which were similar to those of ribavirin. The antiviral activity of favipiravir against the SSPE virus was demonstrated for the first time in this study.
CITATION STYLE
Hashimoto, K., Maeda, H., Miyazaki, K., Watanabe, M., Norito, S., Maeda, R., … Hosoya, M. (2021). Antiviral effect of favipiravir (T-705) against measles and subacute sclerosing panencephalitis viruses. Japanese Journal of Infectious Diseases, 74(2), 154–156. https://doi.org/10.7883/yoken.JJID.2020.481
Mendeley helps you to discover research relevant for your work.